Why the study?
Although international guidelines recommend adenosine as first-line therapy for pediatric paroxysmal supraventricular tachycardia (PSVT) and caution against neonatal propafenone use, propafenone is widely used for acute cardioversion in China with limited real-world efficacy and safety data in neonates and young infants.
Population
70 children with first-onset acute PSVT (per-protocol set, n = 45)
Comparison
Propafenone-centered stepwise cardioversion regimen across pediatric age groups
Design
Single-center retrospective age-stratified clinical effectiveness study
Follow-up
24-hour
Answers are grounded in this paper and cite their sources.
Retrospective study reports 100% 24-hour cardioversion with a propafenone regimen in pediatric PSVT, highlighting limited neonatal efficacy and predictive value of NT-proBNP.
Background Paroxysmal supraventricular tachycardia (PSVT) is the most common symptomatic arrhythmia in children. While international guidelines recommend adenosine as first-line therapy and caution against propafenone use in neonates, propafenone is widely used for acute cardioversion across pediatric age groups in China, with limited real-world efficacy and safety data in neonates and young infants. Methods This single-center retrospective clinical effectiveness study included 70 children with first-onset acute PSVT treated with a propafenone-centered stepwise cardioversion regimen. The 24-hour cardioversion efficacy was evaluated primarily in the per-protocol set (PPS, n = 45), with the full analysis set (FAS, n = 70) used for sensitivity verification. Firth's penalized logistic regression was applied to identify predictors of high treatment difficulty (requiring second-line or higher interventions), and the Jonckheere–Terpstra test to assess age-related trends in myocardial injury biomarkers. The discriminative performance of the prediction model was evaluated using receiver operating characteristic (ROC) curve analysis. Results The stepwise cardioversion regimen achieved an overall 24-hour sinus rhythm conversion rate of 100%. Propafenone achieved an overall cardioversion success rate of 55.7% in the FAS (all first-line administration) and 71.1% for standardized first-line monotherapy in the PPS. All 4 neonates required escalation to second-line or higher interventions, with no response to first-line propafenone monotherapy in the 2 exposed cases. Treatment difficulty decreased significantly with advancing age ( P = 0.001), as did serum hs-cTnT ( P = 0.004), CK-MB ( P < 0.001) and NT-proBNP ( P < 0.001). In multivariable Firth's penalized regression (68 complete cases, 4 core covariates), NT-proBNP was an independent predictor of higher treatment difficulty ( P < 0.001). The prediction model yielded an AUC of 0.718 (95%CI:0.597–0.839, P = 0.002) with moderate exploratory discriminative performance. No severe treatment-related adverse events were observed. Conclusions The propafenone-centered stepwise cardioversion regimen achieves favorable efficacy and acceptable short-term safety for first-onset PSVT in children aged ≥1year. Evidence in neonates remains very limited, so routine first-line propafenone is not recommended in this age group. The multivariable model offers moderate exploratory predictive value, with NT-proBNP identified as an independent predictor of treatment difficulty in this cohort.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: